<DOC>
	<DOCNO>NCT01528878</DOCNO>
	<brief_summary>The purpose study determine tolerable dose radiation deliver CyberKnife system two group patient hepatocellular carcinoma ( HCC ) .</brief_summary>
	<brief_title>Safety , Efficacy , Dosing Stereotactic Radiosurgery Hepato-cellular Carc/Colo-rectal Liver Metastases</brief_title>
	<detailed_description>The CyberKnife system clear U.S. Food Drug Administration ( FDA ) treat lesion , tumor condition anywhere body radiation treatment indicate . In order treat tumor respiratory cycle ( vs. increase margin treatment around tumor compensate movement require patient breath hold delivery beam ) , Synchronyâ„¢ option , system option enable dynamic radiosurgery respiration , use . The purpose study determine tolerable dose radiation deliver CyberKnife two group patient hepatocellular carcinoma ( HCC ) .Group 1 : Patients HCC Childs A cirrhosis , patient colorectal liver metastasis . Group 2 : Patients Childs B cirrhosis . Patients irradiated radiation dos use CyberKnife system 3-5 radiation fraction use guidance fiducials place interventional radiology . Treatments deliver standard CyberKnife procedure account respiratory motion set variation . The fiducial location prime determinant delivery site respiratory motion fiducial marker place via percutaneous approach interventional radiology .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<criteria>1 . Hepatocellular carcinoma ( define biopsy alphafetoprotein ( AFP ) great 1000ng/dL appropriate imaging ) liver metastases colorectal cancer tumor ( define biopsy elevated CEA positive PET scan conjunction mass CT MRI patient previously resect cancer ) . Patients least one measurable liver lesion 3 eligible meet eligibility criterion include dose constraint composite plan . 2 . ECOG performance status 01 . 3 . Patients candidate definitive surgical resection tumor location , hepatic function , medical personal reason . 4 . Patients HCC consider liver transplant may enter bridge transplant consider transplant team ablative therapy would value await transplant . 5 . If cirrhosis present , patient ChildPugh score A B ( see Appendix A Master Protocol ) . 6 . Patients tumor optimally treat radiofrequency ablation interventional radiology , GI/transplant surgery . This could reason size , tumor location , reason . 7 . Ability place fiducial marker vicinity tumor allow radiographic track respiratory motion tumor localization . Fiducial placement generally do interventional radiology . 8 . Estimates hepatic tolerance must meet criterion define Section III . This eligibility able make definitively patient agree participate . study appropriate scan analysis dosimetry perform . No one decrement dose plan dose level allow individual patient exceed maximal liver dose patient declare ineligible study . 9 . Adequate bone marrow renal function assess follow : Absolute neutrophil count ( ANC ) &gt; 1000/mm3 Platelet count &gt; 80,000/mm3 Creatinine &lt; 2.0 mg/dL OR Creatinine clearance &gt; 45 mL/min base CockcroftGault formula ) . 10 . Patients extra hepatic metastatic disease eligible opinion treat physician local therapy liver may produce worthwhile clinical benefit 11 . Patient able understand fully potential risk benefit approach sign appropriate informed consent . 12 . Male female &gt; 18 year age . Male female patient capable reproduction must agree use medically acceptable method contraception , intrauterine device , diaphragm , spermicide , condom spermicide abstinence . Inclusion females childbearing potential require negative pregnancy test within 14 day prior study initiation . 1 . ChildPugh Class C cirrhosis 2 . Patients clinically apparent CNS disease . 3 . Medical psychiatric illness would allow patient tolerate propose treatment include inability lie flat extend period time , severe claustrophobia reason . 4 . Uncontrolled significant cardiovascular disease include : myocardial infarction within 6 month , uncontrolled angina within 6 month , Class IIIIV New York Heart Association ( NYHA ) congestive heart failure , grade 3 cardiac valve dysfunction 5 . Evidence decompensated liver disease evidence : clinically significant ascites refractory diuretic therapy ) evidence hepatic encephalopathy , coagulopathy correct conservative measure . 6 . A history CTC Grade 3 bleed esophageal gastric varix within past 2 month . Prior variceal bleed permit patient undergone band sclerotherapy evidence bleed 2 month . Patients risk varix ( base following : know history esophageal gastric varix ; evidence hepatic cirrhosis and/or portal hypertension include biopsyproven cirrhosis , hypersplenism , radiographic finding varix ) screen esophageal varix . If varix identify require intervention ( band ) , patient eligible varix adequately treat . 7 . Prisoners patient compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g. , infectious disease ) illness must enrol study . 8 . Uncontrolled intercurrent illness . 9 . Inability comply study and/or followup procedure . 10 . A patient ChildPugh Class A eligible study liver dose constraint describe Section 3.2 meet two decrement dose per fraction describe . 11 . A patient ChildPugh Class B eligible study liver dose constraint describe Section 3.2 meet two decrement dose per fraction described .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Liver Cancer</keyword>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>HCC</keyword>
	<keyword>Metastatic Cancer Liver</keyword>
	<keyword>Metastatic Colon Cancer</keyword>
	<keyword>Metastatic Colo-rectal Cancer</keyword>
	<keyword>mCRC</keyword>
	<keyword>Liver Function</keyword>
	<keyword>Child-Pugh</keyword>
</DOC>